Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe

Archive ouverte

Horgan, Denis | Curigliano, Giuseppe | Riess, Olaf | Hofman, Paul | Büttner, Reinhard | Conte, Pierfranco | Cufer, Tanja | Gallagher, William | Georges, Nadia | Kerr, Keith | Penault-Llorca, Frédérique | Mastris, Ken | Pinto, Carla | van Meerbeeck, Jan | Munzone, Elisabetta | Thomas, Marlene | Ujupan, Sonia | Vainer, Gilad | Velthaus, Janna-Lisa | André, Fabrice

Edité par CCSD ; MDPI -

International audience. Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation, and therefore patient access, varies across Europe; a multi-stakeholder collaboration is needed to establish the conditions required to improve this discrepancy. In that regard, we set up European Alliance for Personalised Medicine (EAPM)-led expert panels during the first half of 2021, including key stakeholders from across 10 European countries covering medical, economic, patient, industry, and governmental expertise. We describe the outcomes of these panels in order to define and explore the necessary conditions for NGS implementation into routine clinical care to enable patient access, identify specific challenges in achieving them, and make short- and long-term recommendations. The main challenges identified relate to the demand for NGS tests (governance, clinical standardization, and awareness and education) and supply of tests (equitable reimbursement, infrastructure for conducting and validating tests, and testing access driven by evidence generation). Recommendations made to resolve each of these challenges should aid multi-stakeholder collaboration between national and European initiatives, to complement, support, and mutually reinforce efforts to improve patient care.

Consulter en ligne

Suggestions

Du même auteur

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

Archive ouverte | Horgan, Denis | CCSD

International audience

Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine

Archive ouverte | Horgan, Denis | CCSD

International audience. Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health syst...

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Archive ouverte | Kos, Zuzana | CCSD

International audience. Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical ...

Chargement des enrichissements...